Global Medical Metal Tubing Market– Drivers
Increasing prevalence of chronic diseases
Increasing prevalence of chronic diseases is expected to drive the global medical metal tubing market growth over the forecast period. For instance, according to the World Health Organization (WHO), February 2022, cancer is the largest cause of mortality in the globe, accounting for almost 10 million fatalities in 2020 or one in every six deaths. Breast (2.26 million cases), lung (2.21 million cases), colon and rectum (1.93 million cases), prostate (1.41 million cases), skin (non-melanoma) (1.20 million cases), and stomach (1.09 million cases) were the most prevalent in 2020.
Increasing launches of new tubing
Increasing launch of new and more efficient tubes is expected to drive the global medical metal tubing market growth. For instance, on May 18, 2022, Freudenberg Medical, a Germany-based manufacturer of medical and pharmaceutical devices, introduced HelixFlex, a tubing designed for use in pharmaceutical and biopharmaceutical applications. This is an expanded offering from Freudenberg, adding to its existing pharma product portfolio of silicone tubing and fluid transfer products for bioprocessing, drug, and vaccine manufacturing, filling and sampling, peristaltic pumping, laboratory, and medical device applications. HelixFlex tubing is ideal for pharmaceutical bioprocessing applications because it can be welded to existing tubing lines, and heat-sealed to allow for easy, fast and safe fluid handling, transport, and transfer in biopharma processes. HelixFlex tubing from Freudenberg also offers many different sterilization options including autoclave, gamma irradiation, x-ray, and e-beam. Additionally, metal tubing is a more environmentally friendly option than silicone and can be recycled.
Restraints & Challenges
Recalls of metal tubing and accessories
The recalls of medical metal tubing and its accessories can hinder growth of market. For instance, on August 18, 2021, U.S. Food and Drug Administration announced recall of ZOOM 71 Reperfusion Catheter and Tubing, product of Imperative Care Inc., a U.S.-based biotechnology company, which is used to remove blood clots in the brain of a patient within eight hours of an acute ischemic stroke caused by blocked or narrowed arteries. Company is recalling specific lots of this product due to increased risk of the Zoom 71 Reperfusion Catheter breaking at a certain point (distal tip) during use, such as when the catheter is retracted forcefully. If the device breaks during use, this could lead to fractured pieces left inside the patient’s bloodstream resulting in serious adverse events such as blockage of blood vessels, stroke, and death.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients